Last Updated : May 23, 2023
Details
Generic Name:
vutrisiran
Project Status:
Pending
Therapeutic Area:
Hereditary transthyretin mediated amyloidosis
Manufacturer:
Alnylam Netherlands B.V.
Call for patient/clinician input open:
Brand Name:
Amvuttra
Project Line:
Reimbursement Review
Project Number:
SR0801-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Treatment of hereditary transthyretin mediated amyloidosis (hATTR amyloidosis) in adults.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Amvuttra (vutrisiran) is indicated for the treatment of hereditary transthyretin mediated amyloidosis (hATTR amyloidosis) in adults.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : May 23, 2023